@article{AOI5267,
author = {Jeniel E. Nett},
title = {Invasive candidiasis trial supports echinocandins for primary therapy},
journal = {Annals of Infection},
volume = {3},
number = {0},
year = {2019},
keywords = {},
abstract = {Candida, the most prevalent hospital-associated fungal pathogen, causes a variety of mucosal and deep-seated infections (1). Candidemia and other invasive Candida infections are among the more difficult to treat infections and are associated with high mortality rates, near 40% (2). Neutropenia, often related to chemotherapy or hematologic malignancy, places patients at high risk for severe disseminated candidiasis (3). The current recommended therapy involves a combination of treatment with antifungals, debridement and/or drainage of intra-abdominal sources, and removal of infected devices, such as vascular catheters and implantable cardiac devices (2,4-7).},
issn = {2616-2709}, url = {https://aoi.amegroups.org/article/view/5267}
}